Pooled data shows tazemetostat safe, effective in patients with epithelioid sarcoma
Tazemetostat provides clinically meaningful, durable, single agent activity in patients with epithelioid sarcoma, according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
In the open-label, multicenter, multi-cohort phase 2 study, 44 patients treated with tazemetostat 800 mg per day were included in Cohort 6. In this cohort, objective response rate was 11.4%; 9.1% of patients had a partial response and 2.3% had a complete response. In addition, 38.6% of patients had stable disease.
At 56 weeks, progression-free survival was 19.4% and overall survival was 59.4%.
A post-hoc analysis of patients from Cohorts 5 and 6 (N =106), objective response rate was 13.2%.
Most common grade 3–4 adverse events were anemia and tumor pain.
Mrinal M, et al. Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma. Presented at: the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.